Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 477

1.

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreño F, Albajar Viñas P, Palma PP.

PLoS Negl Trop Dis. 2009 Jul 7;3(7):e488. doi: 10.1371/journal.pntd.0000488.

2.

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.

Escribà JM, Ponce E, Romero Ade D, Viñas PA, Marchiol A, Bassets G, Palma PP, Lima MA, Zúniga C, Ponce C.

Mem Inst Oswaldo Cruz. 2009 Nov;104(7):986-91.

3.

Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM.

Lancet. 1996 Nov 23;348(9039):1407-13.

PMID:
8937280
4.

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.

Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A.

Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63. doi: 10.1586/14787210.7.2.157. Review.

PMID:
19254164
5.

Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.

Alvarez MG, Vigliano C, Lococo B, Petti M, Bertocchi G, Viotti R.

Trans R Soc Trop Med Hyg. 2012 Oct;106(10):636-8. doi: 10.1016/j.trstmh.2012.07.010. Epub 2012 Aug 13.

PMID:
22898619
6.

High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala.

Brum-Soares L, Cubides JC, Burgos I, Monroy C, Castillo L, González S, Viñas PA, Urrutia PP.

Rev Soc Bras Med Trop. 2016 Nov-Dec;49(6):721-727. doi: 10.1590/0037-8682-0415-2016.

7.

Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia.

Chippaux JP, Salas-Clavijo AN, Postigo JR, Schneider D, Santalla JA, Brutus L.

Trans R Soc Trop Med Hyg. 2013 Jan;107(1):1-7. doi: 10.1093/trstmh/trs004.

PMID:
23296694
8.

Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.

Carrilero B, Murcia L, Martínez-Lage L, Segovia M.

Rev Esp Quimioter. 2011 Sep;24(3):123-6.

9.

Long term evaluation of etiological treatment of chagas disease with benznidazole.

Cancado JR.

Rev Inst Med Trop Sao Paulo. 2002 Jan-Feb;44(1):29-37.

10.

Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease.

Pinto AY, Valente Vda C, Coura JR, Valente SA, Junqueira AC, Santos LC, Ferreira AG Jr, de Macedo RC.

PLoS One. 2013 May 27;8(5):e64450. doi: 10.1371/journal.pone.0064450. Print 2013.

11.

Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A.

N Engl J Med. 2014 May 15;370(20):1899-908. doi: 10.1056/NEJMoa1313122.

12.

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.

Álvarez MG, Hernández Y, Bertocchi G, Fernández M, Lococo B, Ramírez JC, Cura C, Albizu CL, Schijman A, Abril M, Sosa-Estani S, Viotti R.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):833-7. doi: 10.1128/AAC.00745-15. Print 2016 Feb.

13.

Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.

Rumi MM, Pérez Brandán C, Gil JF, D'Amato AM, Ragone PG, Lauthier JJ, Tomasini N, Cimino RO, Orellana V, Lacunza CD, Nasser JR, Basombrío MA, Diosque P.

Acta Trop. 2013 Oct;128(1):130-6. doi: 10.1016/j.actatropica.2013.07.003. Epub 2013 Jul 20.

PMID:
23880286
14.

Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.

Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C.

Am J Trop Med Hyg. 1998 Oct;59(4):526-9.

PMID:
9790423
15.

Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.

Manarin R, Lamas MC, Bottasso E, Serra E, Revelli S, Salomón CJ.

Parasitol Int. 2013 Feb;62(1):79-81. doi: 10.1016/j.parint.2012.09.001. Epub 2012 Sep 10.

PMID:
22975280
16.

Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain.

Navarro M, Norman FF, Pérez-Molina JA, López-Vélez R.

Am J Trop Med Hyg. 2012 Sep;87(3):489-90. doi: 10.4269/ajtmh.2012.12-0080. Epub 2012 Jul 23.

17.

[Control of the transmission of Trypanosoma cruzi in Argentina 1999].

Segura EL, Sosa Estani S, Esquivel ML, Gómez A, Salomon OD.

Medicina (B Aires). 1999;59 Suppl 2:91-6. Spanish.

PMID:
10668249
18.

Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.

Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J.

Antimicrob Agents Chemother. 2013 Jan;57(1):390-5. doi: 10.1128/AAC.01401-12. Epub 2012 Oct 31.

19.

Adverse events after the use of benznidazole in infants and children with Chagas disease.

Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H.

Pediatrics. 2011 Jan;127(1):e212-8. doi: 10.1542/peds.2010-1172. Epub 2010 Dec 20.

PMID:
21173000
20.

Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.

Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M.

J Antimicrob Chemother. 2010 Aug;65(8):1759-64. doi: 10.1093/jac/dkq201. Epub 2010 Jun 11.

PMID:
20542903

Supplemental Content

Support Center